Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Surrozen (SRZN) reported its Q4 and full year 2024 financial results, highlighting a strategic focus on ophthalmology pipeline programs. The company secured a two-tranche financing of $175M in gross proceeds to fund multiple ophthalmology programs through Phase 1 studies.
Key financial metrics for 2024 include:
- Cash position of $34.6M as of December 31, 2024
- Additional gross proceeds of $76.4M from March 2025 financing
- Collaboration revenue of $10M from BI milestone
- Research and development expenses decreased to $21.1M from $27.2M in 2023
- Net loss increased to $63.6M compared to $43M in 2023
The company received confirmation that Boehringer will advance SZN-413 toward clinical testing and completed a research collaboration with TCGFB for antibody development targeting TGF-β.
Surrozen (SRZN) ha riportato i risultati finanziari del quarto trimestre e dell'intero anno 2024, evidenziando un focus strategico sui programmi di ricerca in oftalmologia. L'azienda ha assicurato un finanziamento in due tranche di 175 milioni di dollari in proventi lordi per finanziare diversi programmi oftalmologici attraverso studi di Fase 1.
I principali indicatori finanziari per il 2024 includono:
- Posizione di cassa di 34,6 milioni di dollari al 31 dicembre 2024
- Proventi lordi aggiuntivi di 76,4 milioni di dollari dal finanziamento di marzo 2025
- Entrate da collaborazioni di 10 milioni di dollari da un traguardo di BI
- Le spese per ricerca e sviluppo sono diminuite a 21,1 milioni di dollari rispetto ai 27,2 milioni di dollari del 2023
- La perdita netta è aumentata a 63,6 milioni di dollari rispetto ai 43 milioni di dollari del 2023
L'azienda ha ricevuto conferma che Boehringer porterà avanti SZN-413 verso i test clinici e ha completato una collaborazione di ricerca con TCGFB per lo sviluppo di anticorpi mirati a TGF-β.
Surrozen (SRZN) informó sus resultados financieros del cuarto trimestre y del año completo 2024, destacando un enfoque estratégico en los programas de investigación en oftalmología. La compañía aseguró un financiamiento en dos tramos de 175 millones de dólares en ingresos brutos para financiar múltiples programas de oftalmología a través de estudios de Fase 1.
Los principales indicadores financieros para 2024 incluyen:
- Posición de efectivo de 34,6 millones de dólares al 31 de diciembre de 2024
- Ingresos brutos adicionales de 76,4 millones de dólares del financiamiento de marzo de 2025
- Ingresos por colaboración de 10 millones de dólares de un hito de BI
- Los gastos en investigación y desarrollo disminuyeron a 21,1 millones de dólares desde 27,2 millones de dólares en 2023
- La pérdida neta aumentó a 63,6 millones de dólares en comparación con 43 millones de dólares en 2023
La compañía recibió confirmación de que Boehringer avanzará SZN-413 hacia pruebas clínicas y completó una colaboración de investigación con TCGFB para el desarrollo de anticuerpos dirigidos a TGF-β.
Surrozen (SRZN)은 2024년 4분기 및 연간 재무 결과를 보고하며, 안과 프로그램에 대한 전략적 초점을 강조했습니다. 이 회사는 1상 연구를 통해 여러 안과 프로그램을 자금 지원하기 위해 총 1억 7500만 달러의 두 단계 자금을 확보했습니다.
2024년 주요 재무 지표는 다음과 같습니다:
- 2024년 12월 31일 기준 현금 보유액 3천460만 달러
- 2025년 3월 자금 조달로 인한 추가 총 수익 7천640만 달러
- BI 이정표로 인한 협력 수익 1천만 달러
- 연구 및 개발 비용이 2023년 2천720만 달러에서 2천110만 달러로 감소
- 순손실이 2023년 4천300만 달러 대비 6천360만 달러로 증가
회사는 Boehringer가 SZN-413을 임상 시험으로 진행할 것이라는 확인을 받았으며, TGF-β를 표적으로 하는 항체 개발을 위한 TCGFB와의 연구 협력을 완료했습니다.
Surrozen (SRZN) a publié ses résultats financiers du quatrième trimestre et de l'année complète 2024, mettant en avant un focus stratégique sur les programmes en ophtalmologie. L'entreprise a sécurisé un financement en deux tranches de 175 millions de dollars en produits bruts pour financer plusieurs programmes ophtalmologiques à travers des études de phase 1.
Les principaux indicateurs financiers pour 2024 incluent:
- Position de trésorerie de 34,6 millions de dollars au 31 décembre 2024
- Produits bruts supplémentaires de 76,4 millions de dollars provenant du financement de mars 2025
- Revenus de collaboration de 10 millions de dollars provenant d'un jalon de BI
- Les dépenses de recherche et développement ont diminué à 21,1 millions de dollars contre 27,2 millions de dollars en 2023
- La perte nette a augmenté à 63,6 millions de dollars par rapport à 43 millions de dollars en 2023
L'entreprise a reçu la confirmation que Boehringer fera avancer SZN-413 vers des tests cliniques et a complété une collaboration de recherche avec TCGFB pour le développement d'anticorps ciblant TGF-β.
Surrozen (SRZN) hat seine Finanzzahlen für das vierte Quartal und das gesamte Jahr 2024 veröffentlicht und dabei einen strategischen Fokus auf Programme in der Augenheilkunde hervorgehoben. Das Unternehmen sicherte sich eine Finanzierung in zwei Tranchen über 175 Millionen Dollar in Bruttoeinnahmen, um mehrere Programme in der Augenheilkunde durch Phase-1-Studien zu finanzieren.
Wichtige Finanzkennzahlen für 2024 umfassen:
- Liquidität von 34,6 Millionen Dollar zum 31. Dezember 2024
- Zusätzliche Bruttoeinnahmen von 76,4 Millionen Dollar aus der Finanzierung im März 2025
- Kooperationsumsätze von 10 Millionen Dollar aus einem Meilenstein von BI
- Forschung- und Entwicklungskosten sanken auf 21,1 Millionen Dollar von 27,2 Millionen Dollar im Jahr 2023
- Der Nettverlust stieg auf 63,6 Millionen Dollar im Vergleich zu 43 Millionen Dollar im Jahr 2023
Das Unternehmen erhielt die Bestätigung, dass Boehringer SZN-413 in die klinische Testphase überführen wird und hat eine Forschungskooperation mit TCGFB zur Entwicklung von Antikörpern, die auf TGF-β abzielen, abgeschlossen.
- Secured $175M financing for ophthalmology programs
- Received $76.4M gross proceeds in March 2025
- Achieved $10M milestone payment from Boehringer collaboration
- Reduced R&D expenses by $6.1M through restructuring
- Boehringer advancing SZN-413 toward clinical testing
- Net loss increased to $63.6M from $43M in 2023
- Cash position declined from $36M to $34.6M year-over-year
- Interest income decreased to $1.7M from $2.3M in 2023
- $20.4M loss on issuance of stock and warrants
- Other expenses increased by $19.7M due to warrant liabilities
Insights
Surrozen's Q4/FY2024 results present a mixed financial picture with strategic positives counterbalanced by concerning metrics. The company secured a substantial
Revenue generation improved markedly in 2024, with
However, concerning elements include a widened net loss of
Surrozen's strategic pivot to ophthalmology, Boehringer's commitment to advance SZN-413 toward clinical testing, and the significant financing must be weighed against the substantial net losses. The cash infusion significantly strengthens the balance sheet but dilution impacts and warrant complexities create financial friction that may continue to affect performance metrics.
Surrozen's strategic refocusing on ophthalmology represents a promising pipeline narrowing that better leverages their proprietary Wnt pathway modulation platform. By concentrating resources on severe eye diseases, the company appears to be targeting conditions where their technology's regenerative potential could potentially address significant unmet needs, though specific indications aren't detailed in the announcement.
The advancement of SZN-413 by Boehringer Ingelheim toward clinical testing validates Surrozen's platform technology and suggests the candidate demonstrated sufficient preclinical promise to warrant continued development. This external validation from a major pharmaceutical partner adds credibility to Surrozen's approach to Wnt pathway modulation.
The company's mention of nominating "a portfolio of novel preclinical ophthalmology candidates for severe eye diseases" indicates pipeline expansion within their new focus area, suggesting multiple shots on goal rather than a single-candidate strategy. The successful
The research collaboration with TCGFB leveraging Surrozen's antibody development capabilities for TGF-β targeting further demonstrates the versatility of their technology platform beyond just Wnt modulation. This suggests potential for additional partnerships and revenue streams beyond their internal pipeline, potentially creating value beyond their ophthalmology focus.
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today provided fourth quarter and full year 2024 financial results and business updates.
Research and Development Pipeline Highlights
The company prioritized its ophthalmology pipeline programs that have the potential to provide new or improved treatment options in multiple severe and disabling eye diseases. Surrozen will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs including development of new treatment options for retinopathies.
Other Business Highlights
The company also completed the first closing of a two-tranche financing of
“In 2024, we continued to leverage our research capabilities and significant expertise in antibody engineering technologies focused on Wnt signal modulation. We received notification that Boehringer planned to further develop SZN-413 to advance the compound and prepare it for clinical testing, nominated a portfolio of novel preclinical ophthalmology candidates for severe eye diseases and completed a research collaboration with TCGFB to utilize Surrozen’s antibody developments capabilities and expertise to discover antibodies targeting TGF-β” said Craig Parker, President and Chief Executive Officer of Surrozen. “More recently, we were pleased to announce a private financing to advance our novel ophthalmology-focused pipeline toward the clinic”
Financial Results for the Fourth Quarter and Full Year 2024
Cash Position: Cash and cash equivalents were
Collaboration and License Revenue: Collaboration and license revenue for the fourth quarter and full year ended December 31, 2024 was zero and
Research Service Revenue – Related Party: Research service revenue – related party for the fourth quarter and full year ended December 31, 2024 was both
Research and Development Expenses: Research and development expenses for the fourth quarter and full year ended December 31, 2024 were
General and Administrative Expenses: General and administrative expenses for the fourth quarter and full year ended December 31, 2024 were
Restructuring: Restructuring charges for the fourth quarter and full year ended December 31, 2024 were both zero, as compared to
Interest Income: Interest income for the fourth quarter and full year ended December 31, 2024 was
Loss on Issuance of Common Stock, Pre-Funded Warrants and Warrants: Loss on issuance of common stock, pre-funded warrants and warrants for the fourth quarter and full year ended December 31, 2024 was zero and
Other (Expense) Income, Net: Other (expense) income, net for the fourth quarter and full year ended December 31, 2024 was a net other expense of
Net Loss: Net loss for the fourth quarter and full year ended December 31, 2024 was
About Ophthalmology Portfolio
About SZN-8141 for retinal diseases
SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). The current standard of care for diabetic retinopathy (including DME), retinal vein occlusion and wet AMD is intravitreal administration of anti-VEGF monotherapies. In addition, Fzd4 monotherapy has demonstrated proof of concept in clinical trials. We believe SZN-8141 has the potential to treat multiple retinopathy indications and be differentiated from existing therapies. Data generated in preclinical models of retinopathy demonstrated that SZN-8141 stimulated Wnt signaling and induced normal retinal vessel regrowth while suppressing pathological vessel growth.
About SZN-8143 for retinal diseases
SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema (UME). The current standard of care for diabetic retinopathy (including DME), retinal vein occlusion and wet AMD is intravitreal administration of anti-VEGF monotherapies. In addition, Fzd4 monotherapy has demonstrated proof of concept in clinical trials. We believe SZN-8143 has the potential to treat multiple retinopathy indications and be differentiated from existing therapies. Data generated in preclinical models of retinopathy demonstrated that SZN-8143 stimulated Wnt signaling and induced normal retinal vessel regrowth while suppressing pathological vessel growth.
About SZN-413 for Retinal Diseases
SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP™ technology. It is currently being developed for the treatment of retinal vascular-associated diseases. Data generated by Surrozen with SZN-413 in preclinical models of retinopathy demonstrated that SZN-413 could potently stimulate Wnt signaling in the eye, induce normal retinal vessel regrowth, suppress pathological vessel growth and reduce vascular leakage. This novel approach could thus potentially allow for regeneration of healthy eye tissue, not only halting retinopathy, but possibly allowing for a full reversal of the patient’s disease.
About Surrozen
Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus in ophthalmology.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, the availability of data, the potential for such product candidates to be used to treat human disease, as well as the potential benefits of such product candidates), the Company’s partnership with Boehringer Ingelheim, including the potential for future success-based development, regulatory, and commercial milestone payments, in addition to mid-single digit to low-double digit royalties on sales and the potential of TGF-β to be a novel, first-in-class therapeutic to treat the pathology of Idiopathic Pulmonary Fibrosis. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates and potential future drug candidates; the Company’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for Sits product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor/Media Contact:
Email: Investorinfo@surrozen.com
SURROZEN, INC. | ||||||||
Consolidated Statements of Operations | ||||||||
(In thousands, except per share amounts) | ||||||||
Year Ended December 31, | ||||||||
2024 | 2023 | |||||||
Collaboration and license revenue | $ | 10,000 | $ | — | ||||
Research service revenue – related party | 655 | — | ||||||
Total revenue | 10,655 | — | ||||||
Operating expenses: | ||||||||
Research and development | 21,132 | 27,230 | ||||||
General and administrative | 15,062 | 15,798 | ||||||
Restructuring | — | 2,752 | ||||||
Total operating expenses | 36,194 | 45,780 | ||||||
Loss from operations | (25,539 | ) | (45,780 | ) | ||||
Interest income | 1,693 | 2,340 | ||||||
Loss on issuance of common stock, pre-funded warrants and warrants | (20,397 | ) | — | |||||
Other (expense) income, net | (19,321 | ) | 398 | |||||
Net loss | $ | (63,564 | ) | $ | (43,042 | ) | ||
Net loss per share attributable to common stockholders, basic and diluted | $ | (21.67 | ) | $ | (21.33 | ) | ||
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 2,933 | 2,018 |
SURROZEN, INC. | ||||||||
Consolidated Balance Sheets | ||||||||
(In thousands) | ||||||||
December 31, | ||||||||
2024 | 2023 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 34,565 | $ | 36,043 | ||||
Accounts receivable | 2,039 | 2,152 | ||||||
Accounts receivable – related party | 502 | — | ||||||
Prepaid expenses and other current assets | 1,826 | 2,937 | ||||||
Total current assets | 38,932 | 41,132 | ||||||
Property and equipment, net | 562 | 1,969 | ||||||
Operating lease right-of-use assets | 7,801 | 1,889 | ||||||
Restricted cash | 688 | 688 | ||||||
Warrant asset | 153 | — | ||||||
Other assets | 331 | 402 | ||||||
Total assets | $ | 48,467 | $ | 46,080 | ||||
Liabilities and stockholders’ (deficit) equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 306 | $ | 525 | ||||
Accrued and other liabilities | 5,180 | 4,126 | ||||||
Lease liabilities, current portion | 1,829 | 2,497 | ||||||
Total current liabilities | 7,315 | 7,148 | ||||||
Lease liabilities, noncurrent portion | 6,640 | 882 | ||||||
Warrant liabilities | 55,892 | 115 | ||||||
Total liabilities | 69,847 | 8,145 | ||||||
Stockholders’ (deficit) equity: | ||||||||
Preferred stock | — | — | ||||||
Common stock | — | — | ||||||
Additional paid-in-capital | 263,879 | 259,630 | ||||||
Accumulated deficit | (285,259 | ) | (221,695 | ) | ||||
Total stockholders’ (deficit) equity | (21,380 | ) | 37,935 | |||||
Total liabilities and stockholders’ (deficit) equity | $ | 48,467 | $ | 46,080 |
